Cerebrospinal fluid (CSF) core biomarkers (Aβ1–42, p-Tau, and total-Tau), as well as amyloid and Tau positron-emission tomography, reliably reflect AD neuropathological brain lesions3,4, leading to their inclusion in research diagnostic criteria. Here, MAPT is linked to Alzheimer disease.